Digestive and Liver Disease
Volume 42, Issue 4 , Pages 297-303 , April 2010

Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression

  • Raffaella Lionetti

      Affiliations

    • Hepatology Unit, University of Rome “Tor Vergata”, Via Montpellier, 1, 00133 Rome, Italy
    • ,
  • Giuseppe Tisone

      Affiliations

    • Liver Transplant Unit, University of Rome “Tor Vergata”, Via Montpellier, 1, 00133 Rome, Italy
    • ,
  • Giampiero Palmieri

      Affiliations

    • Department of Pathological Anatomy, University of Rome “Tor Vergata”, Via Montpellier, 1 00133 Rome, Italy
    • ,
  • Cristiana Almerighi

      Affiliations

    • Hepatology Unit, University of Rome “Tor Vergata”, Via Montpellier, 1, 00133 Rome, Italy
    • ,
  • Alessandra Anselmo

      Affiliations

    • Liver Transplant Unit, University of Rome “Tor Vergata”, Via Montpellier, 1, 00133 Rome, Italy
    • ,
  • Laura Tariciotti

      Affiliations

    • Liver Transplant Unit, University of Rome “Tor Vergata”, Via Montpellier, 1, 00133 Rome, Italy
    • ,
  • Ilaria Lenci

      Affiliations

    • Hepatology Unit, University of Rome “Tor Vergata”, Via Montpellier, 1, 00133 Rome, Italy
    • ,
  • Linda De Luca

      Affiliations

    • Liver Transplant Unit, University of Rome “Tor Vergata”, Via Montpellier, 1, 00133 Rome, Italy
    • ,
  • Andrea Monaco

      Affiliations

    • Hepatology Unit, University of Rome “Tor Vergata”, Via Montpellier, 1, 00133 Rome, Italy
    • ,
  • Mario Angelico

      Affiliations

    • Hepatology Unit, University of Rome “Tor Vergata”, Via Montpellier, 1, 00133 Rome, Italy
    • Corresponding Author InformationCorresponding author at: Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università di Roma Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy. Tel.: +39 06 7259 6803; fax: +39 06 7259 6803.

Received 24 June 2009 ,Accepted 31 August 2009.

References 

  1. Zarski JP, Mc Hutchinson J, Bronowicki JP, et al. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol. 2003;38:307–314
  2. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124:97–104
  3. Sanchez Fueyo A, Restrepo J, Quinto L, et al. Impact of recurrence of HCV infection after liver transplantation on the long term viability of graft. Transplantation. 2002;73:56–63
  4. Berenguer N, Ferrell L, Watson J, et al. HCV-related fibrosis progression after liver transplantation: increase in recent years. J Hepatol. 2000;32:673–684
  5. Gane E, Portmann B, Naoumov N, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815–820
  6. Poynard T, McHutchinson J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis. Gastroenterology. 2002;122:1303–1313
  7. Zeuzem S, Feinman V, Rasenack J, et al. Peginterferon alfa 2a in patients with chronic hepatitis C. N Eng J Med. 2000;23:1666–1672
  8. Heathcote J, Shiffman M, Graham W, et al. Peginterferon alfa 2a in patients with chronic hepatitis C and cirrhosis. N Eng J Med. 2000;23:1673–1680
  9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med. 2002;347:975–982
  10. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965
  11. National institute of health consensus development conference statement: management of hepatitis C. Hepatology. 2002;36:S1–S15
  12. Berenguer M. Natural history of recurrent hepatitis C. Liver Transplant. 2002;10:S14–18
  13. Berenguer M, Aguilera V, Prieto M, et al. Delayed onset of severe hepatitis C related liver damage following liver transplantation: a matter of concern?. Liver Transplant. 2003;9:1152–1158
  14. Dumortier J, Scoazec JY, Chevallier P, et al. Treatment of recurrent hepatitis C after liver transplantation: pilot study of peginterferon alfa 2b and ribavirin combination. J Hepatol. 2004;4:669–674
  15. Rodriguez Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha and ribavirin: an open-label study. Transplantation. 2004;77:190–194
  16. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005;41:289–298
  17. Samuel D, Bizollon T, Feray C, et al. Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation. A randomized study. Gastroenterology. 2003;124:642–650
  18. Abdelmalek MF, Firpi R, Soldevila-Pico C, et al. Sustained virological response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplant. 2004;10:199–207
  19. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology. 1997;26:500–504
  20. Alberti AB, Belli LS, Airoldi A, et al. Combined therapy with interferon and low dose of ribavirin in post-transplantation recurrent hepatitis C: a pragmatic study. Liver Transplant. 2001;7:870–876
  21. Shakil AO, Mc Guire B, Crippin J, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology. 2002;36:1253–1258
  22. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transplant. 2002;8:1000–1006
  23. Ross AS, Bham AK, Pascual M, et al. Pegylated interferon alfa-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant. 2002;18:166–173
  24. Neff GW, Montalbano M, O’Brien CB, et al. Treatment of established recurrent hepatitis C in liver transplant recipients with pegylated interferon alfa-2b and ribavirin therapy. Transplantation. 2004;78:1303–1307
  25. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology. 1995;22:1084–1089
  26. Saab S, Kalmaz D, Gajjar N, et al. Outcome of acute rejection after interferon therapy in liver transplant recipients. Liver Transplant. 2004;10(7):859–867
  27. Kuo A, Terrault NA. Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters?. J Hepatology. 2007;46:359–361
  28. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004;126(3):703–714
  29. Lau N, Tam R, Liang J, et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35:1002–1009
  30. Tam R, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol. 1999;30:376–382
  31. Vollmer J, Rankin R, Hartmann H, et al. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother. 2004;48:2314–2317
  32. Zhang Y, Jamaluddin M, Wang S, et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol. 2003;77:5933–5947
  33. Dixit NM, Layden J, Layden T, et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004;432:922–924
  34. Hoofnagle J, Ghany M, Kleiner D, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology. 2003;38:66–74
  35. Patel K, Dev A, Muir A, McHutchison JG. Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?. Hepatology. 2003;38(21):24
  36. Bizollon T, Ahmed SN, Radenne S, et al. Long-term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained virological response to interferon–ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut. 2003;52:283–287
  37. Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane hepato-biliary group systematic review and meta-analysis of randomized trial. Am J Gastroenterol. 2006;101(4):842–847
  38. Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003;39:239–244
  39. Demetris AJ, Ruppert K. Pathologist's perspective on liver needle biopsy size?. J Hepatol. 2003;39:275–277
  40. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449–1457
  41. Scheuer PJ. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology. 2003;38:1356–1358
  42. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699
  43. Neumann P, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830–836
  44. Angelico M, Petrolati A, Lionetti RG, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol. 2007;46:1009–1017
  45. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transplant. 2003;9:S28–S34
  46. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation?. J Hepatol. 2005;42:448–479
  47. Baiocchi L, Angelico M, Petrolati A, et al. Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease. Am J Transplant. 2008;8(3):673–678
  48. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol. 2006;44:702–709
  49. Kamar N, Chatelut E, Manolis E, et al. Rivabirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis. 2004;43:140–146

PII: S1590-8658(09)00367-3

doi: 10.1016/j.dld.2009.08.008

Digestive and Liver Disease
Volume 42, Issue 4 , Pages 297-303 , April 2010

Article Tools